Terns Pharmaceuticals Undergoes Leadership Changes as it Navigates the Path to Addressing Serious Diseases
FOSTER CITY, Calif. May 08, 2024 - Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company with a focus on developing small-molecule product candidates to tackle severe diseases such as oncology and obesity, has announced significant leadership changes. The company has appointed Scott Harris as the new Chief Development Officer (CDO), effective May 28, 2024. Concurrently, the current President and Head of Research and Development, Dr. Erin Quirk, will be leaving the position on June 3, 2024, to explore alternative opportunities.
Terns Pharmaceuticals has been at the forefront of cutting-edge research and development, striving to address some of today’s most challenging health conditions. The introduction of Scott Harris as CDO marks another milestone in the company’s growth and commitment to advancing its product portfolio further.
Mr. Harris brings a wealth of experience to Terns Pharmaceuticals, having held leadership positions in reputable biopharmaceutical companies. With a strong track record of success in drug development and commercialization, he is well-versed in navigating the complexities of the industry. His expertise will be instrumental in driving Terns’ clinical development programs and strengthening the company’s pipeline.
Dr. Quirk, who has played a pivotal role in Terns’ research and development efforts, will be transitioning her responsibilities to ensure a smooth handover. During her tenure, she spearheaded numerous innovative projects, contributing significantly to the advancement of the company’s mission. As Dr. Quirk moves on to explore new opportunities, Terns Pharmaceuticals wishes her well and expresses gratitude for her valuable contributions.
The departure of Dr. Quirk and the appointment of Mr. Harris reflect Terns Pharmaceuticals’ commitment to continuous growth and adaptation as it endeavors to improve patient outcomes. By leveraging the expertise of Mr. Harris and the existing talent within the company, Terns Pharmaceuticals aims to accelerate its development programs and address critical unmet medical needs in the fields of oncology and obesity.
With its robust portfolio of small-molecule product candidates, Terns Pharmaceuticals is poised to make a significant impact on the treatment landscape. The company’s dedication to scientific excellence, coupled with a patient-centric approach, positions it as a key player in the biopharmaceutical industry. Terns Pharmaceuticals’ ability to attract top talent, as seen in the appointment of Mr. Harris, underscores its commitment to advancing its innovative therapies and transforming the lives of patients globally.
As Terns Pharmaceuticals embarks on this new chapter, it remains focused on its core mission to develop breakthrough treatments for serious diseases that have a tangible impact on patients’ lives. The company’s leadership changes signify a strategic evolution and a strong commitment to nurturing a world-class team that will drive innovation, accelerate development timelines, and ultimately deliver effective therapies to those in need.
Comments